Published in BJU Int on July 15, 2014
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
Role of VHL gene mutation in human cancer. J Clin Oncol (2004) 5.46
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
2004 WHO classification of the renal tumors of the adults. Eur Urol (2006) 4.85
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol (2013) 4.24
Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol (2011) 3.51
Renal tumor biopsies for evaluation of small renal tumors: why, in whom, and how? Eur Urol (2008) 2.97
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med (2012) 2.95
The new cytogenetics: blurring the boundaries with molecular biology. Nat Rev Genet (2005) 2.68
The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. J Urol (2008) 2.15
Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol (2012) 1.95
Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am J Surg Pathol (2011) 1.64
Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol (1994) 1.62
High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer (2009) 1.55
Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol (2009) 1.55
2009 update on the classification of renal epithelial tumors in adults. Int J Urol (2009) 1.43
Xp11.2 translocation renal cell carcinoma. Arch Pathol Lab Med (2010) 1.36
Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer (2009) 1.33
Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer (2009) 1.32
Contemporary management of small renal masses. Eur Urol (2011) 1.19
Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res (2009) 1.16
Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful? Arch Pathol Lab Med (2012) 1.12
Clinical genomics of renal epithelial tumors. Cancer Genet (2011) 1.05
Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis. Cancer Res (2001) 1.04
Renal cell carcinoma sub-typing by histopathology and fluorescence in situ hybridization on a needle-biopsy specimen. BJU Int (2006) 1.01
Renal mass sampling: an enlightened perspective. Int J Urol (2010) 0.99
Small renal mass: to treat or not to treat. Curr Urol Rep (2013) 0.99
Specific genetic changes of diagnostic importance in chromophobe renal cell carcinomas. Lab Invest (1997) 0.98
The current role of percutaneous biopsy of renal masses. Can J Urol (2012) 0.97
Biopsy of a renal mass: where are we now? Curr Opin Urol (2009) 0.96
Diagnosis of renal tumors on needle biopsy specimens by histological and molecular analysis. J Urol (2006) 0.96
Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies. Genes Chromosomes Cancer (2010) 0.88
Three genetic developmental stages of papillary renal cell tumors: duplication of chromosome 1q marks fatal progression. Int J Cancer (2009) 0.87
Small renal masses: toward more rational treatment. Cleve Clin J Med (2011) 0.87
CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma. Hum Pathol (2009) 0.85
Genomic imbalances in 61 renal cancers from the proximal tubulus detected by comparative genomic hybridization. Cytogenet Cell Genet (2001) 0.85
Genomic deregulation during metastasis of renal cell carcinoma implements a myofibroblast-like program of gene expression. Cancer Res (2010) 0.84
Evolving role of renal biopsy in small renal masses. Urol Oncol (2009) 0.84
Multi-colour FISH on preoperative renal tumour biopsies to confirm the diagnosis of uncertain renal masses. World J Urol (2010) 0.82
PCR-based RFLP screening of the commonly deleted 3p loci in renal cortical neoplasms. Diagn Mol Pathol (1993) 0.82
Statistical treatment of fluorescence in situ hybridization validation data to generate normal reference ranges using Excel functions. J Mol Diagn (2009) 0.82
The application of cytogenetics and fluorescence in situ hybridization to fine-needle aspiration in the diagnosis and subclassification of renal neoplasms. Cancer Cytopathol (2010) 0.81
Comparative study of renal cell carcinoma by CGH, multicolor-FISH and conventional cytogenic banding analysis. Oncol Rep (2005) 0.81
Renal cell neoplasms contain shared tumor type-specific copy number variations. Am J Pathol (2012) 0.81
What is the added value of combined core biopsy and fine needle aspiration in the diagnostic process of renal tumours? World J Urol (2011) 0.80
Renal oncocytomas with 11q13 rearrangements: cytogenetic, molecular, and immunohistochemical analysis of cyclin D1. Cancer Genet Cytogenet (2004) 0.79
Characterization of quantitative chromosomal abnormalities in renal cell carcinomas by interphase four-color fluorescence in situ hybridization. Cancer Genet Cytogenet (2005) 0.77
Many facets of chromosome 3p cytogenetic findings in clear cell renal carcinoma: the need for agreement in assessment FISH analysis to avoid diagnostic errors. Histol Histopathol (2011) 0.77
Fine needle aspiration of renal cortical lesions in adults. Diagn Cytopathol (2010) 0.77
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet (2008) 5.66
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell (2005) 3.39
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med (2006) 3.14
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med (2012) 2.95
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer (2005) 2.78
Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol (2013) 2.76
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol (2003) 2.67
Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. Proc Natl Acad Sci U S A (2009) 2.57
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood (2009) 2.36
Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol (2009) 2.32
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res (2007) 2.32
Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol (2008) 2.30
Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer (2008) 2.29
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26
Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology (2007) 2.23
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood (2002) 2.13
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Chemotherapy for teratoma with malignant transformation. J Clin Oncol (2003) 2.06
Management of low grade papillary bladder tumors. J Urol (2007) 2.04
Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid (2014) 2.04
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02
Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell (2011) 2.01
Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol (2009) 1.98
Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol (2004) 1.97
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol (2004) 1.95
Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res (2006) 1.94
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol (2013) 1.92
Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol (2009) 1.91
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol (2002) 1.90
Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol (2008) 1.89
Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histology. J Urol (2004) 1.81
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell (2016) 1.79
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol (2007) 1.76
Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology (2012) 1.74
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol (2003) 1.74
Expression of the AID protein in normal and neoplastic B cells. Blood (2004) 1.73
Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol (2010) 1.73
Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer (2003) 1.73
Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol (2006) 1.69
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res (2009) 1.68
Granular cell tumor of the breast: a series of 17 cases and review of the literature. Breast J (2004) 1.64
Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am J Surg Pathol (2011) 1.64
SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res (2010) 1.64
Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J Immunol (2006) 1.62
PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol (2002) 1.59
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res (2014) 1.57
Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings. Radiology (2008) 1.56
Protective effects of plasma carotenoids on the risk of bladder cancer. J Urol (2006) 1.56
Anterior-predominant prostatic tumors: zone of origin and pathologic outcomes at radical prostatectomy. Am J Surg Pathol (2008) 1.56
Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody. Cancer Res (2006) 1.56
Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol (2004) 1.55
Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology (2009) 1.55
Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol (2005) 1.54
Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJU Int (2010) 1.54
Urachal carcinoma: contemporary surgical outcomes. J Urol (2007) 1.53
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol (2007) 1.51
Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery (2008) 1.50
Expanding the histologic spectrum of mucinous tubular and spindle cell carcinoma of the kidney. Am J Surg Pathol (2006) 1.50
Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer (2007) 1.50
FISH analysis in addition to G-band karyotyping: utility in evaluation of myelodysplastic syndromes? Leuk Res (2009) 1.50
Impact of a multidisciplinary continuous quality improvement program on the positive surgical margin rate after laparoscopic radical prostatectomy. Eur Urol (2006) 1.50
Prostatic transition zone directed needle biopsies uncommonly sample clinically relevant transition zone tumors. J Urol (2009) 1.49
Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol (2008) 1.49
Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection. Mod Pathol (2012) 1.46
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol (2010) 1.44
Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer (2006) 1.44
Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change. Am J Surg Pathol (2009) 1.43
Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol (2014) 1.43
Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005. J Urol (2008) 1.43
Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res (2008) 1.42
An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst (2013) 1.42
Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol (2007) 1.41